Design, synthesis and biological evaluation of novel FGFR inhibitors bearing an indazole scaffold.
Liu, J., Peng, X., Dai, Y., Zhang, W., Ren, S., Ai, J., Geng, M., Li, Y.(2015) Org Biomol Chem 13: 7643-7654
- PubMed: 26080733 
- DOI: https://doi.org/10.1039/c5ob00778j
- Primary Citation of Related Structures:  
4ZSA - PubMed Abstract: 
Fibroblast growth factor receptor (FGFR) is a potential target for cancer therapy. Based on the structure of AZD4547 and NVPBGJ-398, we designed novel 1H-indazol-3-amine scaffold derivatives by utilizing scaffold hopping and molecular hybridization strategies. Consequently, twenty-eight new compounds were synthesized and evaluated for their inhibitory activity against FGFR1. Compound 7n bearing a 6-(3-methoxyphenyl)-1H-indazol-3-amine scaffold was first identified as a potent FGFR1 inhibitor, with good enzymatic inhibition (IC50 = 15.0 nM) and modest cellular inhibition (IC50 = 642.1 nM). The crystal structure of 7n bound to FGFR1 was obtained, which might provide a new basis for potent inhibitor design. Further structural optimization revealed that compound 7r stood out as the most potent FGFR1 inhibitor with the best enzyme inhibitory (IC50 = 2.9 nM) and cellular activity (IC50 = 40.5 nM).
Organizational Affiliation: 
School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, China. liyx417@fudan.edu.cn.